Over 100 Emerging Biotech Companies Choose Veeva Basics to Streamline Operations

More than 100 Emerging Biotech Companies Adopt Veeva Basics

In a significant development for the biotechnology sector, over 100 emerging biotech companies have chosen Veeva Basics, a stripped-down version of the comprehensive Veeva Vault platform, designed to facilitate streamlined operations in clinical, regulatory, and quality management processes. Veeva Systems Inc. (NYSE: VEEV) announced this milestone during the recent Veeva R&D and Quality Summit held in Boston, where industry leaders gathered to discuss innovations and set future directions for Veeva Basics.

Veeva Basics empowers smaller biotech firms to leverage best-in-class applications that are preconfigured and validated for quick deployment, laying a robust foundation for their operational growth. The framework offers a smooth transition for companies that may later require a more complete Vault solution, thus avoiding cumbersome data migration challenges. This flexibility is crucial as biotech companies navigate the evolving demands of the industry.

With Veeva Basics, companies can access vital tools tailored to meet the industry's rigorous requirements without the overwhelming complexity often associated with large-scale software solutions. The product's primary aim is to build operational efficiency now while providing the necessary support for long-term scalability.

Steve Harper, General Manager of Veeva Basics, expressed pride in the positive impact that the platform is making in the biotech sector. He emphasized the momentum generated during the summit, where over 100 leaders from 60 companies explored how Veeva Basics could enable swift implementation of innovative applications that support new drug development.

New Applications to Boost Efficiency

To satisfy increasingly critical quality control and commercial needs, Veeva Basics introduces two innovative solutions:

1. Veeva LIMS Basics - Optimized for virtual companies, this application caters to the needs of marketing directors. It handles batch release and generates Certificates of Analysis (CoA), ensuring a streamlined quality management process. A stability functionality is projected for 2026, enhancing its capability further.

2. Veeva PromoMats Basics - This application provides comprehensive management of promotional content throughout its lifecycle, from approval to storage and distribution. Its features also facilitate complaint management, thus ensuring compliance with promotional standards.

Both applications are anticipated to be available by early 2026 and are built on the proven Vault platform, which enhances their potential to scale alongside growing businesses.

Testimonials from Industry Leaders

Numerous emerging biotech companies have praised Veeva Basics for its seamless integration into their existing frameworks. Richard Tornai, Senior Director of IT at Structure Therapeutics, mentioned how critical it was for their rapidly growing business to standardize operations according to best practices. He noted that the platform not only delivers immediate solutions but also ensures a smooth path to advanced Vault capabilities as they expand.

Bryan Ball, Operations Director at Whitehawk Therapeutics, highlighted the necessity of establishing a robust quality and compliance foundation with a cost-effective solution. He expressed confidence in Veeva Basics, emphasizing its logical workflows, template library for SOPs, and easy-to-use training components.

Bernhard Irlinger, Quality Head at AiCuris, shared his appreciation of Veeva Basics for its state-of-the-art solutions and global support, which empowers rapid staff training. He acknowledged Veeva’s commitment to innovation and customer success, making it an ideal partner.

About Veeva Systems

Veeva has positioned itself as a leader in cloud solutions for life sciences, offering software, data, and consulting services. With a commitment to innovation, product excellence, and client success, Veeva serves over 1,500 customers ranging from large biopharmaceutical corporations to emerging biotech startups. As a Public Benefit Corporation, Veeva strives to balance the interests of all its stakeholders, including customers, employees, investors, and the broader industries it serves. More information can be found at veeva.com/eu.

Cautionary Note

This release contains forward-looking statements about Veeva’s products and anticipated outcomes from their usage, reliant on current expectations that may differ materially from actual results. Numerous risks could adversely affect these results, details of which can be found in Veeva’s quarterly report (Form 10-Q) for the period ending July 31, 2025. The report is accessible for review on sec.gov.

For further inquiries, please contact Jeremy Whittaker at Veeva Systems.